Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.

An oncolytic HSV vector comprising an NF-B response element or an Oct-3/4-SOX2 response element in a regulatory region of a viral gene that affects viral replication efficiency.

An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.

Disclosed are a biological entity for treating brain cancer, in particular glioma, and a vector including the biological entity. The biological entity is a construct including at least anti-tumor transgenes comprised of at least one GluA knockdown agent, and preferably at least two GluA knockdown agents, and preferably further includes a fusogenic protein, and immune response promotors of an anti-PD-1 antibody, an anti-CTLA-4 antibody and an IL12. The vector comprises a wild-type HSV-1 virus wherein the biological entity replaces the ICP 34.5 gene of the wild HSV-1 virus. The vector comprising wild type HSV-1 virus modified with the biological entity shows little negative effect on neurons while showing positive effect against human glioblastoma cells, both separately cultured and in co-cultures of neuronal cells and glioblastoma cells.

The present disclosure relates to replication-competent controlled herpesviruses whose transient replication in an inoculation site of a subject can be activated by the delivery of an appropriate heat dose to the inoculation site region. In related recombinant viruses, activation requires delivery of a heat dose in the presence in the inoculation site of an effective concentration of a small-molecule regulator. The viruses are engineered to express an antigen from a SARS CoV-2 virus and are expected to induce strong and balanced immune responses against the SARS CoV-2 antigen in subjects to which they are administrated.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

Provided herein are bispecific adaptor proteins and their use for retargeting oncolytic HSV to target cells, such as tumor cells.

The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.

Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.

Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.